For decades, cancer has been doing something that sounds almost impossible when you first hear it.
It hides.
Not behind a tumor. Not behind symptoms. It hides from the very immune system that is supposed to destroy it.
And now researchers may have found a way to expose it.
A new experimental drug developed by Oxford-based Greywolf Therapeutics is generating excitement after early trial results showed it helped shrink tumors across six different cancer types. The treatment doesn’t attack cancer directly. Instead, it appears to do something many scientists have been trying to accomplish for years: strip away cancer’s ability to disguise itself.
Think about that for a second.
The body’s immune system is incredibly good at finding foreign invaders. Viruses show up? The immune system notices. Harmful bacteria appear? The alarms go off. Specialized immune cells move in and begin the fight.
Cancer is different because it starts as the body’s own cells.
Somewhere along the line, those cells mutate and become dangerous. The problem is that they still carry many of the biological markers that tell the immune system they belong there. In many cases, cancer cells produce proteins that effectively help them blend into the crowd. It’s like a criminal wearing the same uniform as the police.
The immune system walks right past the threat.
That’s where this new drug enters the picture.
The treatment, known as GRWD5769, works by targeting a mechanism cancer uses to stay hidden. Researchers say it can remove what some scientists have described as an “invisibility cloak,” allowing T-cells—the immune system’s frontline fighters—to recognize and attack tumor cells that previously escaped detection.
And the early numbers are turning heads.
A clinical trial involving 83 patients across the United Kingdom, France, Spain, and Australia tested the drug alongside the immunotherapy treatment cemiplimab. Participants suffered from cervical, bladder, liver, bowel, lung, or head and neck cancers.
The results showed tumors shrank in 26 patients. Even more notable, 15 of those patients experienced tumor reductions of at least 30%.
Researchers also reported disease progression was halted for at least six months in significant portions of patients across several cancer categories. The rates ranged from 18% among cervical cancer patients to as high as 55% among lung cancer patients.
Those numbers may not sound dramatic to someone outside the medical field, but cancer researchers tend to be extremely cautious with their language. That’s why comments from Professor Fiona Thistlethwaite attracted attention during the American Society of Clinical Oncology’s annual meeting in Chicago.
She described the findings as showing “strong signals of efficacy” across six tumor types that have historically been resistant to immunotherapy treatments.
Even more striking, she noted the limited side effects observed during the early-stage trial.
“For a drug that is given as a tablet, this is very impressive,” Thistlethwaite told The Guardian. “It’s early days, and we need further studies, but this is a new drug with a new mechanism that clearly helps immunotherapy perform more effectively.”
That last point is important.
Researchers are not claiming they’ve discovered a cure for cancer. The study remains in its early stages, and larger trials will be needed before any firm conclusions can be reached. But what has scientists excited is the possibility of improving immunotherapy, one of the most significant advances in cancer treatment over the past several decades.
Immunotherapy has transformed outcomes for many patients, yet it has always had a frustrating limitation: it doesn’t work for everyone.
Sometimes the immune system simply cannot see what it’s supposed to attack.
Dr. Samuel Godfrey of Cancer Research UK says this new approach may help address that problem.
“Immunotherapy has transformed treatment for some cancers,” Godfrey explained. “This trial seems to show how this new drug could make immunotherapy more effective, including in some cases where immunotherapy had previously failed.”
For cancer patients and their families, that possibility alone is worth paying attention to.
After years of watching cancer win the hide-and-seek game, researchers may finally have found a way to turn on the lights.